Gossamer bio announces second quarter 2025 financial results and provides business update

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced its financial results for the second quarter ended june 30, 2025, and provided a business update. gossamer bio and the chiesi group are jointly developing seralutinib un.
GOSS Ratings Summary
GOSS Quant Ranking